{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+eye+drops",
    "query": {
      "intervention": "Placebo eye drops"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 363,
    "total_pages": 37,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+eye+drops&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-10T02:35:08.124Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01119287",
      "title": "Assessing the Efficacy of Maxidex® and Patanol® for the Treatment of Allergic Conjunctivitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Allergic Conjunctivitis"
      ],
      "interventions": [
        {
          "name": "Dexamethasone 0.1% ophthalmic suspension",
          "type": "DRUG"
        },
        {
          "name": "Olopatadine hydrochloride 0.1% ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "Inactive ingredients, used as placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Alcon Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 180,
      "start_date": "2010-03",
      "completion_date": "2010-09",
      "has_results": true,
      "last_update_posted_date": "2014-02-28",
      "last_synced_at": "2026-09-10T02:35:08.124Z",
      "location_count": 1,
      "location_summary": "Fort Worth, Texas",
      "locations": [
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01119287"
    },
    {
      "nct_id": "NCT05066698",
      "title": "ST266 Eyedrops for the Treatment of Persistent Corneal Epithelial Defects",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Persistent Corneal Epithelial Defect"
      ],
      "interventions": [
        {
          "name": "ST266",
          "type": "BIOLOGICAL"
        },
        {
          "name": "0.67% Sodium Chloride Ophthalmic Solution",
          "type": "OTHER"
        },
        {
          "name": "Open-label ST266",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Noveome Biotherapeutics, formerly Stemnion",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2022-04-27",
      "completion_date": "2022-09-07",
      "has_results": false,
      "last_update_posted_date": "2022-10-25",
      "last_synced_at": "2026-09-10T02:35:08.124Z",
      "location_count": 31,
      "location_summary": "Dothan, Alabama • Little Rock, Arkansas • Huntington Beach, California + 23 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05066698"
    },
    {
      "nct_id": "NCT03248037",
      "title": "Trial of Netarsudil for Prevention of Corticosteroid-induced Intraocular Pressure Elevation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Fuchs' Endothelial Dystrophy",
        "Bullous Keratopathy"
      ],
      "interventions": [
        {
          "name": "Netarsudil",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cornea Research Foundation of America",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2017-09-05",
      "completion_date": "2019-07-09",
      "has_results": true,
      "last_update_posted_date": "2021-02-12",
      "last_synced_at": "2026-09-10T02:35:08.124Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03248037"
    },
    {
      "nct_id": "NCT02436759",
      "title": "Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acquired Blepharoptosis"
      ],
      "interventions": [
        {
          "name": "RVL-1201",
          "type": "DRUG"
        },
        {
          "name": "RVL-1201 Vehicle Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "RVL Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 140,
      "start_date": "2015-05",
      "completion_date": "2016-11",
      "has_results": true,
      "last_update_posted_date": "2021-10-28",
      "last_synced_at": "2026-09-10T02:35:08.124Z",
      "location_count": 14,
      "location_summary": "Artesia, California • Newport Beach, California • Rancho Cordova, California + 11 more",
      "locations": [
        {
          "city": "Artesia",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Rancho Cordova",
          "state": "California"
        },
        {
          "city": "Santa Maria",
          "state": "California"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02436759"
    },
    {
      "nct_id": "NCT04268069",
      "title": "Efficacy and Safety of PL9643 Ophthalmic Solution in Subjects With Dry Eye",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dry Eye Disease"
      ],
      "interventions": [
        {
          "name": "PL9643 Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Placebo Ophthalmic Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ORA, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 160,
      "start_date": "2020-02-14",
      "completion_date": "2020-10-05",
      "has_results": false,
      "last_update_posted_date": "2020-11-13",
      "last_synced_at": "2026-09-10T02:35:08.124Z",
      "location_count": 4,
      "location_summary": "Andover, Massachusetts • Raynham, Massachusetts • Shelby, North Carolina + 1 more",
      "locations": [
        {
          "city": "Andover",
          "state": "Massachusetts"
        },
        {
          "city": "Raynham",
          "state": "Massachusetts"
        },
        {
          "city": "Shelby",
          "state": "North Carolina"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04268069"
    },
    {
      "nct_id": "NCT02653391",
      "title": "A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for the Treatment of Fuchs' Corneal Endothelial Dystrophy (FCED)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Fuchs' Corneal Endothelial Dystrophy (FCED)"
      ],
      "interventions": [
        {
          "name": "Part A Elamipretide 1.0% Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Part B Elamipretide 3.0% Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Part A Placebo",
          "type": "DRUG"
        },
        {
          "name": "Part B Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stealth BioTherapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2016-02",
      "completion_date": "2018-12",
      "has_results": true,
      "last_update_posted_date": "2021-09-17",
      "last_synced_at": "2026-09-10T02:35:08.124Z",
      "location_count": 2,
      "location_summary": "Edgewood, Kentucky • Boston, Massachusetts",
      "locations": [
        {
          "city": "Edgewood",
          "state": "Kentucky"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02653391"
    },
    {
      "nct_id": "NCT04792580",
      "title": "The Effects and Safety of 5% Lifitegrast Ophthalmic Solution in Subjects With Dry Eye Disease in Ocular Graft-versus-Host Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Graft-versus-host-disease",
        "Ocular Graft-versus-host Disease"
      ],
      "interventions": [
        {
          "name": "Lifitegrast 5% Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Richard W Yee, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 30,
      "start_date": "2022-10-22",
      "completion_date": "2024-04-30",
      "has_results": false,
      "last_update_posted_date": "2024-07-15",
      "last_synced_at": "2026-09-10T02:35:08.124Z",
      "location_count": 1,
      "location_summary": "Bellaire, Texas",
      "locations": [
        {
          "city": "Bellaire",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04792580"
    },
    {
      "nct_id": "NCT01633788",
      "title": "A Study of AGN-195263 for the Treatment of Meibomian Gland Dysfunction",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Meibomian Gland Dysfunction"
      ],
      "interventions": [
        {
          "name": "AGN-195263 0.1%",
          "type": "DRUG"
        },
        {
          "name": "AGN-195263 0.03%",
          "type": "DRUG"
        },
        {
          "name": "AGN-195263 0.01%",
          "type": "DRUG"
        },
        {
          "name": "AGN-195263 Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 232,
      "start_date": "2012-08-22",
      "completion_date": "2015-02-05",
      "has_results": true,
      "last_update_posted_date": "2017-09-08",
      "last_synced_at": "2026-09-10T02:35:08.124Z",
      "location_count": 33,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Artesia, California + 29 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Artesia",
          "state": "California"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01633788"
    },
    {
      "nct_id": "NCT03216902",
      "title": "A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Open-angle Glaucoma, Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "Vehicle of DE-126 Ophthalmic Solution, high dose of DE-126 Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Topical ultra-low dose of DE-126 Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Topical low dose of DE-126 Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Topical medium dose of DE-126 Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Topical high dose of DE-126 Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "0.005% Latanoprost Ophthalmic Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Santen Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 241,
      "start_date": "2017-07-25",
      "completion_date": "2018-02-27",
      "has_results": true,
      "last_update_posted_date": "2020-10-23",
      "last_synced_at": "2026-09-10T02:35:08.124Z",
      "location_count": 12,
      "location_summary": "Artesia, California • Mission Hills, California • Newport Beach, California + 9 more",
      "locations": [
        {
          "city": "Artesia",
          "state": "California"
        },
        {
          "city": "Mission Hills",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Petaluma",
          "state": "California"
        },
        {
          "city": "Largo",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03216902"
    },
    {
      "nct_id": "NCT04806503",
      "title": "A Dose-ranging Study to Evaluate the Safety and Efficacy of UNR844 in Subjects With Presbyopia.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Presbyopia"
      ],
      "interventions": [
        {
          "name": "UNR844",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "45 Years to 55 Years"
      },
      "enrollment_count": 234,
      "start_date": "2021-06-30",
      "completion_date": "2022-10-14",
      "has_results": true,
      "last_update_posted_date": "2024-06-20",
      "last_synced_at": "2026-09-10T02:35:08.124Z",
      "location_count": 12,
      "location_summary": "Laguna Hills, California • Newport Beach, California • Largo, Florida + 8 more",
      "locations": [
        {
          "city": "Laguna Hills",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Largo",
          "state": "Florida"
        },
        {
          "city": "Lake Villa",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04806503"
    }
  ]
}